Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
20
04
2021
accepted:
13
09
2021
revised:
29
08
2021
pubmed:
1
12
2021
medline:
21
12
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
No extensive studies have investigated current diagnosis and treatment trends of hypogonadism (HG) in adult men in the United States. Using a comprehensive commercial insurance database, we surveyed current trends in incidence, prevalence, and treatment of hypogonadism in the United States. We analyzed insurance claims data from 2008-2017 using the IBM MarketScan™ Commercial Claims and Encounters database for men ≥18. Overall, we estimated annual incidence at 16.1 cases per 100,000 person-years, with the highest incidence seen among men 35-44 years at 21.5 cases per 100,000 person-years (IRR 1.83; 95% CI 1.63, 2.06, p < 0.001) and among those living in the Southern United States at 22.6 cases per 100,000 person-years (IRR 1.96; 95% CI 1.76, 2.18, p < 0.001). The prevalence of HG across the study period increased from 0.78% to 5.4%, while treatment rates decreased from 32.9% to 20.8%. These study findings provide a large-scale view of current diagnosis rates and treatment of hypogonadism in adult men in the United States. Despite the increase in prevalence of disease, there is an observed decline in treatment rates after diagnosis. Further investigations are needed to identify factors driving the observed decline in healthcare utilization among men with hypogonadism.
Identifiants
pubmed: 34845356
doi: 10.1038/s41443-021-00471-2
pii: 10.1038/s41443-021-00471-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
762-768Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200:423–32.
doi: 10.1016/j.juro.2018.03.115
Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. EAU guidelines on male hypogonadism. Eur Assoc of Urol Guidelines. 2015;1:9-12.
Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56:1991–9.
doi: 10.1111/j.1532-5415.2008.01927.x
Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev 2018;6:69–76.
doi: 10.1016/j.sxmr.2017.08.007
Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737–45.
doi: 10.1210/jc.2007-1972
Nguyen CP, Hirsch MS, Moeny D, Kaul S, Mohamoud M, Joffe HV. Testosterone and “age-related hypogonadism”–FDA concerns. N. Engl J Med. 2015;373:689–91.
doi: 10.1056/NEJMp1506632
Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–7.
doi: 10.1210/jc.2007-1245
Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8.
doi: 10.1210/jc.2009-1796
Adamson DMCS, Hansen LG. Health Research Data for the Real World: The MarketScan Databases. 2006.
Bureau US Do CEaSAUSC census regions and divisions of the United States. New England.
Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93:3870–7.
doi: 10.1210/jc.2008-0021
Myers CA, Slack T, Martin CK, Broyles ST, Heymsfield SB. Regional disparities in obesity prevalence in the United States: a spatial regime analysis. Obes (Silver Spring). 2015;23:481–7.
doi: 10.1002/oby.20963
Rao PK, Boulet SL, Mehta A, Hotaling J, Eisenberg ML, Honig SC, et al. Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. J Urol 2017;197:1121–26.
doi: 10.1016/j.juro.2016.10.063
Gold M. Health maintenance organizations: structure, performance, and current issues for employee health benefits design. J Occup Med. 1991;33:288–96.
PharmaceuticalOnline. Testosterone Gel Safety Concerns Prompt FDA To Require Label Changes, Medication Guide. May 2009.
Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices. J Sex Med. 2014;11:553–62.
doi: 10.1111/jsm.12369
Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110:162–9.
doi: 10.1111/j.1464-410X.2011.10837.x